Financhill
Sell
44

XWEL Quote, Financials, Valuation and Earnings

Last price:
$1.06
Seasonality move :
-16.2%
Day range:
$1.01 - $1.04
52-week range:
$0.70 - $2.70
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.15x
P/B ratio:
0.66x
Volume:
20.6K
Avg. volume:
37.5K
1-year change:
-38.92%
Market cap:
$5.4M
Revenue:
$33.9M
EPS (TTM):
-$4.02

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
XWEL
XWELL
-- -- -- -- --
APDN
Applied DNA Sciences
$1.3M -$37.50 27.47% -98.87% --
FONR
Fonar
-- -- -- -- --
IMDX
Insight Molecular Diagnostics
$292K -$0.24 180.72% -33.33% --
PRPH
ProPhase Labs
$3.6M -$0.15 3.99% -50% $13.80
VCYT
Veracyte
$120.9M $0.30 6.44% 332.6% $40.33
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
XWEL
XWELL
$1.02 -- $5.4M -- $0.00 0% 0.15x
APDN
Applied DNA Sciences
$5.03 -- $2.6M -- $0.00 0% 0.06x
FONR
Fonar
$16.09 -- $101.3M 12.87x $0.00 0% 0.99x
IMDX
Insight Molecular Diagnostics
$2.83 -- $80.9M -- $0.00 0% 12.83x
PRPH
ProPhase Labs
$0.37 $13.80 $15.5M -- $0.00 0% 2.02x
VCYT
Veracyte
$25.17 $40.33 $2B 61.39x $0.00 0% 4.30x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
XWEL
XWELL
-- 0.204 -- 1.41x
APDN
Applied DNA Sciences
-- 5.076 -- 3.97x
FONR
Fonar
-- 1.699 -- 9.69x
IMDX
Insight Molecular Diagnostics
-- -1.933 -- 3.57x
PRPH
ProPhase Labs
22.08% -3.124 25.51% 0.84x
VCYT
Veracyte
-- 2.266 -- 4.54x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
XWEL
XWELL
$1.3M -$3.2M -153.74% -153.74% -64.9% -$4.6M
APDN
Applied DNA Sciences
$370.9K -$3.5M -84.02% -84.02% -352.03% -$3.4M
FONR
Fonar
$12.1M $3.7M 5.32% 5.33% 15.23% $2.5M
IMDX
Insight Molecular Diagnostics
$1.3M -$5.9M -693.81% -693.81% -310.66% -$6.2M
PRPH
ProPhase Labs
$526K -$3.7M -101.67% -144.22% -289.24% -$3.4M
VCYT
Veracyte
$79.5M $1.2M 2.85% 2.85% 1.02% $3.5M

XWELL vs. Competitors

  • Which has Higher Returns XWEL or APDN?

    Applied DNA Sciences has a net margin of -67.19% compared to XWELL's net margin of -336%. XWELL's return on equity of -153.74% beat Applied DNA Sciences's return on equity of -84.02%.

    Company Gross Margin Earnings Per Share Invested Capital
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
    APDN
    Applied DNA Sciences
    37.71% -$230.25 $10.2M
  • What do Analysts Say About XWEL or APDN?

    XWELL has a consensus price target of --, signalling upside risk potential of 586.28%. On the other hand Applied DNA Sciences has an analysts' consensus of -- which suggests that it could grow by 447215.88%. Given that Applied DNA Sciences has higher upside potential than XWELL, analysts believe Applied DNA Sciences is more attractive than XWELL.

    Company Buy Ratings Hold Ratings Sell Ratings
    XWEL
    XWELL
    0 0 0
    APDN
    Applied DNA Sciences
    0 1 0
  • Is XWEL or APDN More Risky?

    XWELL has a beta of 0.866, which suggesting that the stock is 13.424% less volatile than S&P 500. In comparison Applied DNA Sciences has a beta of 0.068, suggesting its less volatile than the S&P 500 by 93.226%.

  • Which is a Better Dividend Stock XWEL or APDN?

    XWELL has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Applied DNA Sciences offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL pays -- of its earnings as a dividend. Applied DNA Sciences pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XWEL or APDN?

    XWELL quarterly revenues are $7M, which are larger than Applied DNA Sciences quarterly revenues of $983.4K. XWELL's net income of -$4.7M is lower than Applied DNA Sciences's net income of -$3.3M. Notably, XWELL's price-to-earnings ratio is -- while Applied DNA Sciences's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL is 0.15x versus 0.06x for Applied DNA Sciences. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XWEL
    XWELL
    0.15x -- $7M -$4.7M
    APDN
    Applied DNA Sciences
    0.06x -- $983.4K -$3.3M
  • Which has Higher Returns XWEL or FONR?

    Fonar has a net margin of -67.19% compared to XWELL's net margin of 9.23%. XWELL's return on equity of -153.74% beat Fonar's return on equity of 5.33%.

    Company Gross Margin Earnings Per Share Invested Capital
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
    FONR
    Fonar
    44.52% $0.37 $160.3M
  • What do Analysts Say About XWEL or FONR?

    XWELL has a consensus price target of --, signalling upside risk potential of 586.28%. On the other hand Fonar has an analysts' consensus of -- which suggests that it could fall by --. Given that XWELL has higher upside potential than Fonar, analysts believe XWELL is more attractive than Fonar.

    Company Buy Ratings Hold Ratings Sell Ratings
    XWEL
    XWELL
    0 0 0
    FONR
    Fonar
    0 0 0
  • Is XWEL or FONR More Risky?

    XWELL has a beta of 0.866, which suggesting that the stock is 13.424% less volatile than S&P 500. In comparison Fonar has a beta of 0.998, suggesting its less volatile than the S&P 500 by 0.238%.

  • Which is a Better Dividend Stock XWEL or FONR?

    XWELL has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fonar offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL pays -- of its earnings as a dividend. Fonar pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XWEL or FONR?

    XWELL quarterly revenues are $7M, which are smaller than Fonar quarterly revenues of $27.2M. XWELL's net income of -$4.7M is lower than Fonar's net income of $2.5M. Notably, XWELL's price-to-earnings ratio is -- while Fonar's PE ratio is 12.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL is 0.15x versus 0.99x for Fonar. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XWEL
    XWELL
    0.15x -- $7M -$4.7M
    FONR
    Fonar
    0.99x 12.87x $27.2M $2.5M
  • Which has Higher Returns XWEL or IMDX?

    Insight Molecular Diagnostics has a net margin of -67.19% compared to XWELL's net margin of -312.02%. XWELL's return on equity of -153.74% beat Insight Molecular Diagnostics's return on equity of -693.81%.

    Company Gross Margin Earnings Per Share Invested Capital
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
    IMDX
    Insight Molecular Diagnostics
    61.97% -$0.26 $10.2M
  • What do Analysts Say About XWEL or IMDX?

    XWELL has a consensus price target of --, signalling upside risk potential of 586.28%. On the other hand Insight Molecular Diagnostics has an analysts' consensus of -- which suggests that it could grow by 91.4%. Given that XWELL has higher upside potential than Insight Molecular Diagnostics, analysts believe XWELL is more attractive than Insight Molecular Diagnostics.

    Company Buy Ratings Hold Ratings Sell Ratings
    XWEL
    XWELL
    0 0 0
    IMDX
    Insight Molecular Diagnostics
    0 0 0
  • Is XWEL or IMDX More Risky?

    XWELL has a beta of 0.866, which suggesting that the stock is 13.424% less volatile than S&P 500. In comparison Insight Molecular Diagnostics has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.652%.

  • Which is a Better Dividend Stock XWEL or IMDX?

    XWELL has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insight Molecular Diagnostics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL pays -- of its earnings as a dividend. Insight Molecular Diagnostics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XWEL or IMDX?

    XWELL quarterly revenues are $7M, which are larger than Insight Molecular Diagnostics quarterly revenues of $2.1M. XWELL's net income of -$4.7M is higher than Insight Molecular Diagnostics's net income of -$6.7M. Notably, XWELL's price-to-earnings ratio is -- while Insight Molecular Diagnostics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL is 0.15x versus 12.83x for Insight Molecular Diagnostics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XWEL
    XWELL
    0.15x -- $7M -$4.7M
    IMDX
    Insight Molecular Diagnostics
    12.83x -- $2.1M -$6.7M
  • Which has Higher Returns XWEL or PRPH?

    ProPhase Labs has a net margin of -67.19% compared to XWELL's net margin of -209.38%. XWELL's return on equity of -153.74% beat ProPhase Labs's return on equity of -144.22%.

    Company Gross Margin Earnings Per Share Invested Capital
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
    PRPH
    ProPhase Labs
    36.76% $0.11 $19.4M
  • What do Analysts Say About XWEL or PRPH?

    XWELL has a consensus price target of --, signalling upside risk potential of 586.28%. On the other hand ProPhase Labs has an analysts' consensus of $13.80 which suggests that it could grow by 3609.68%. Given that ProPhase Labs has higher upside potential than XWELL, analysts believe ProPhase Labs is more attractive than XWELL.

    Company Buy Ratings Hold Ratings Sell Ratings
    XWEL
    XWELL
    0 0 0
    PRPH
    ProPhase Labs
    0 0 0
  • Is XWEL or PRPH More Risky?

    XWELL has a beta of 0.866, which suggesting that the stock is 13.424% less volatile than S&P 500. In comparison ProPhase Labs has a beta of -0.412, suggesting its less volatile than the S&P 500 by 141.195%.

  • Which is a Better Dividend Stock XWEL or PRPH?

    XWELL has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL pays -- of its earnings as a dividend. ProPhase Labs pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XWEL or PRPH?

    XWELL quarterly revenues are $7M, which are larger than ProPhase Labs quarterly revenues of $1.4M. XWELL's net income of -$4.7M is lower than ProPhase Labs's net income of $4M. Notably, XWELL's price-to-earnings ratio is -- while ProPhase Labs's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL is 0.15x versus 2.02x for ProPhase Labs. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XWEL
    XWELL
    0.15x -- $7M -$4.7M
    PRPH
    ProPhase Labs
    2.02x -- $1.4M $4M
  • Which has Higher Returns XWEL or VCYT?

    Veracyte has a net margin of -67.19% compared to XWELL's net margin of 6.16%. XWELL's return on equity of -153.74% beat Veracyte's return on equity of 2.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    XWEL
    XWELL
    18.78% -$1.00 $3.4M
    VCYT
    Veracyte
    69.46% $0.09 $1.2B
  • What do Analysts Say About XWEL or VCYT?

    XWELL has a consensus price target of --, signalling upside risk potential of 586.28%. On the other hand Veracyte has an analysts' consensus of $40.33 which suggests that it could grow by 60.24%. Given that XWELL has higher upside potential than Veracyte, analysts believe XWELL is more attractive than Veracyte.

    Company Buy Ratings Hold Ratings Sell Ratings
    XWEL
    XWELL
    0 0 0
    VCYT
    Veracyte
    7 1 1
  • Is XWEL or VCYT More Risky?

    XWELL has a beta of 0.866, which suggesting that the stock is 13.424% less volatile than S&P 500. In comparison Veracyte has a beta of 2.071, suggesting its more volatile than the S&P 500 by 107.062%.

  • Which is a Better Dividend Stock XWEL or VCYT?

    XWELL has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. XWELL pays -- of its earnings as a dividend. Veracyte pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios XWEL or VCYT?

    XWELL quarterly revenues are $7M, which are smaller than Veracyte quarterly revenues of $114.5M. XWELL's net income of -$4.7M is lower than Veracyte's net income of $7M. Notably, XWELL's price-to-earnings ratio is -- while Veracyte's PE ratio is 61.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for XWELL is 0.15x versus 4.30x for Veracyte. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    XWEL
    XWELL
    0.15x -- $7M -$4.7M
    VCYT
    Veracyte
    4.30x 61.39x $114.5M $7M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will GoodRX Stock Bounce Back?
Will GoodRX Stock Bounce Back?

GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…

Will FCX Benefit From Tariffs?
Will FCX Benefit From Tariffs?

Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…

Can Levi Stock Double?
Can Levi Stock Double?

Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…

Stock Ideas

Buy
70
Is NVDA Stock a Buy?

Market Cap: $4.2T
P/E Ratio: 58x

Buy
62
Is MSFT Stock a Buy?

Market Cap: $3.8T
P/E Ratio: 43x

Sell
40
Is AAPL Stock a Buy?

Market Cap: $3.1T
P/E Ratio: 35x

Alerts

Buy
82
SBET alert for Jul 17

SharpLink Gaming [SBET] is down 2.6% over the past day.

Buy
89
EXOD alert for Jul 17

Exodus Movement [EXOD] is down 4.14% over the past day.

Buy
60
U alert for Jul 17

Unity Software [U] is up 7.51% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock